Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

May 26, 2020
Concert Pharmaceuticals to Webcast Fireside Chat at Jefferies Virtual Global Healthcare Conference

May 12, 2020
Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference

© 2020 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top